HOT NEWS
ADLM 2026 | Connecting Global IVD Innovation, Exploring New Paradigms in IVD
As one of the most influential industry events in the field of laboratory medicine worldwide, ADLM 2026 (Association for Diagnostics & Laboratory Medicine) will be held from July 26–30, 2026, in Anaheim, California, USA. It is expected to bring together diagnostic companies, research institutions, clinical laboratories, and industry chain partners from over 100 countries to showcase the latest technologies and innovative achievements in laboratory medicine and in vitro diagnostics. Each year, ADLM attracts hundreds of exhibiting companies and covers a broad spectrum of areas including molecular diagnostics, immunoassays, clinical chemistry, POCT, mass spectrometry, and digital laboratories, making it a vital exchange platform for the global IVD industry.
2026-07-14
On May 12, the strategic signing ceremony between Realbio and Thermo Fisher Scientific, a global leader in scientific services, was successfully held at the Thermo Fisher Customer Experience Center in Shanghai. The two parties will engage in in-depth collaboration on "integrated solutions for in-vitro diagnostic quality control materials," jointly embarking on a new chapter of resource sharing and value co-creation. Attendees at the signing ceremony included Patrick Jones, Global President of Professional Diagnostics at Thermo Fisher; Anuj Dhingra, Global Vice President of Professional Diagnostics; Linda Tang, Commercial Director of Professional Diagnostics, China; Luca Saronni, Global Chief Business Development Manager of Clinical Diagnostics; Liangchao Huang, Senior Sales Manager of Clinical Diagnostics, China; Anita Zhang, Product Specialist of Clinical Diagnostics Marketing, China; as well as Su Shaobo, Chairman of Shenzhen Realbio Group; Jiang Wenyu, Deputy General Manager of Operations; and Ji Hongyu, International Business Development Manager. This signing represents not only a joining of hands between the two enterprises but also another significant milestone for Ruiyali in enhancing its local industrial translation capabilities.
2026-05-12
On April 9, Realbio Group and the Shenzhen CDC officially signed a strategic cooperation agreement in Shenzhen. The two parties will engage in in-depth collaboration on the construction of a clinical translation evaluation system for in-vitro diagnostics (IVD), with the aim of bridging the "last mile" from the laboratory to clinical application, enhancing the industry's regulatory market access capabilities, and contributing to the development of a public service platform for the diagnostics field in the Greater Bay Area.
2026-04-10
Headquarters address: Building 1, Shenfubao Science and Technology Ecological Industrial Park, No. 18 Jinxiu West Road, Pingshan District, Shenzhen
Copyright © 2021 Shenzhen Realbiogroup Co.,Ltd | www.300.cn | Privacy policy
City Substation
Business License